ArticleCVIR endovascular2025
Endovascular techniques for the treatment of true renal arterial aneurysms-procedural insights and outcomes.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management strategies for giant renal artery aneurysms: a systematic review and case report.American journal of clinical and experimental immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo discuss endovascular techniques and report the outcomes for endovascular treatment of true renal arterial aneurysms (TRAAs). MATERIALS AND
methodsA 22-year retrospective analysis of endovascular treatment of TRAAs in our institution. Aneurysm characteristics and endovascular techniques are discussed. Outcome measures were technical and clinical success (need for reintervention), renal parenchymal perfusion loss, impact on renal function, and complications. A 30-day mortality analysis was performed. Impact on renal function was assessed with a two-tailed, paired t-test of pre- and post-procedural serum creatinine.
resultsEighteen endovascular procedures were performed to treat 15 TRAAs in 14 patients (including three reinterventions). 14/15 TRAAs were classified as Type 2 and 1/15 as Type 1 (Rundback classification). Mean initial aneurysm size was 22.9 mm (range 5-40 mm). Of the 14 Type 2 TRAAs, five were initially treated with balloon-assisted Onyx embolisation, four with stent-assisted coiling, four with sac packing, and one with stent-grafting. The technical success rate was 100%. The TRAAs requiring reintervention had been originally treated with balloon-assisted Onyx embolisation (two TRAAs) and stent-grafting (one TRAA). Renal parenchymal loss was < 10% in 10/15 TRAAs after initial intervention. At reintervention, 2/3 cases had 60-70% estimated parenchymal loss as the TRAAs had to be treated more aggressively. Complications (grade 1-3) occurred in 5/18 procedures. The grade 2 complication was atrophy and loss of renal function of the treated kidney (with serum creatinine remaining in the normal range) (n = 1). Grade 3 complications were brachial access pseudoaneurysm (n = 1), common femoral vein thrombosis (n = 1), and access site cellulitis (n = 1).
conclusionEndovascular treatment of TRAAs has a high rate of technical success and a low impact on renal function. A higher rate of reintervention was observed for TRAAs treated with Onyx embolisation, leading to a shift towards stent-assisted coiling as our preferred technique when anatomically feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.